[
1. Yu T-M, Lin C-L, Chang S-N, et al. Osteoporosis and fractures after solid organ transplantation: a nationwide population-based cohort study. In: Mayo Clinic Proceedings. 2014: Abstract 89, p. 888–895. Elsevier.10.1016/j.mayocp.2014.02.01724809760
]Search in Google Scholar
[
2. Pimentel A, Ureña-Torres P, Zillikens MC, et al. Fractures in patients with CKD—diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney international 2017; 92(6): 1343–1355.10.1016/j.kint.2017.07.02128964571
]Search in Google Scholar
[
3. Epstein S, Shane E. Transplantation osteoporosis. Osteoporosis. Elsevier2001, 327–340.10.1016/B978-012470862-4/50053-2
]Search in Google Scholar
[
4. Epstein S, Shane E, Bilezikian JP. Organ transplantation and osteoporosis. Current opinion in Rheumatology 1995; 7(3): 255–261.10.1097/00002281-199505000-000187612420
]Search in Google Scholar
[
5. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis & rheumatology 2017; 69(8): 1521–1537.10.1002/art.4013728585373
]Search in Google Scholar
[
6. Altman AM, Sprague SM. Mineral and bone disease in kidney transplant recipients. Current osteoporosis reports 2018; 16(6): 703–711.10.1007/s11914-018-0490-430390201
]Search in Google Scholar
[
7. Ebeling PR. Transplantation osteoporosis. Current osteoporosis reports 2007; 5(1): 29–37.10.1007/BF0293862017320025
]Search in Google Scholar
[
8. Anastasilakis AD, Tsourdi E, Makras P, et al. Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. Bone 2019.10.1016/j.bone.2019.07.00631299385
]Search in Google Scholar
[
9. Epstein S. Post-transplantation bone disease: The role of immunosuppressive agents and the skeleton. Journal of Bone and Mineral Research 1996; 11(1): 1–7.10.1002/jbmr.56501101028770690
]Search in Google Scholar
[
10. Westenfeld R, Schlieper G, Wöltje M, et al. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis—implications for post-transplantation bone disease. Nephrology Dialysis Transplantation 2011; 26(12): 4115–4123.10.1093/ndt/gfr21421622987
]Search in Google Scholar
[
11. Kneissel M, Luong-Nguyen N-H, Baptist M, et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 2004; 35(5): 1144–1156.10.1016/j.bone.2004.07.01315542040
]Search in Google Scholar
[
12. Glantschnig H, Fisher J, Wesolowski G, et al. M-CSF, TNF α and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death & Differentiation 2003; 10(10): 1165–1177.10.1038/sj.cdd.440128514502240
]Search in Google Scholar
[
13. Hadji P, Coleman R, Gnant M. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Critical reviews in oncology/hematology 2013; 87(2): 101–111.10.1016/j.critrevonc.2013.05.01523838481
]Search in Google Scholar
[
14. Campistol JM, Holt DW, Epstein S, et al. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transplant international 2005; 18(9): 1028–1035.10.1111/j.1432-2277.2005.00163.x16101723
]Search in Google Scholar
[
15. Kanda J, Izumo N, Furukawa M, et al. Effects of the calcineurin inhibitors cyclosporine and tacrolimus on bone metabolism in rats. Biomedical Research 2018; 39(3): 131–139.10.2220/biomedres.39.13129899188
]Search in Google Scholar
[
16. Graziani G, Aroldi A, Castelnovo C, et al. /Ciclosporin and Calcium Metabolism in Renal Transplanted Patients. Nephron 1991; 57(4): 479–480.10.1159/0001863532046833
]Search in Google Scholar
[
17. Ugur A, Guvener N, Isklar I, et al. Osteoporosis after renal transplantation: single center experience. Transplantation 2001; 71(5): 645–649.10.1097/00007890-200103150-0001111292294
]Search in Google Scholar
[
18. Marcén R, Caballero C, Pascual J, et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. Transplantation 2006; 81(6): 826–831.10.1097/01.tp.0000203557.36884.e316570003
]Search in Google Scholar
[
19. Bozkaya G, Nart A, Uslu A, et al. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients. In: Transplantation proceedings. 2008: Abstract 40, p. 151–155. Elsevier.10.1016/j.transproceed.2007.11.04018261573
]Search in Google Scholar
[
20. Mogi M, Kondo A. Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells. Biochemical and biophysical research communications 2009; 384(1): 82–86.10.1016/j.bbrc.2009.04.08419393224
]Search in Google Scholar
